ANI PHARMACEUTICALS INC 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information Our common stock trades on the Nasdaq Global Market under the symbol “ANIP.” Stockholder Information As of March 2, 2023, there were approximately 232 shareholders of record of our common stock, which does not include stockholders that beneficially own shares held in a “nominee” or in “street” name, and six holders of record of Class C stock. Dividends We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Our shares of Series A convertible preferred stock (the “PIPE Shares”), accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. We currently intend to retain all remaining available funds and any future earnings to fund the development and growth of our business. Recent Sales of Unregistered Securities None. Issuer Purchases of Equity Securities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Maximum Number (or ​ ​ ​ ​ ​ ​ ​ Total Number of ​ approximate dollar ​ ​ ​ ​ ​ ​ ​ Shares Purchased as ​ value) of Shares ​ ​ Total Number ​ ​ ​ ​ Part of Publicly ​ that may yet be ​ ​ of Shares ​ Average Price ​ Announced Plans or ​ Purchased Under the Period Purchased (1) Paid per Share Programs Plans or Programs October 1 - October 31, 2022 ​ — ​ $ — ​ — ​ $ — November 1 - November 30, 2022 ​ 2,024 ​ $ 36.60 ​ — ​ $ — December 1 - December 31, 2022 ​ 1,156 ​ $ 39.24 ​ — ​ $ — Total ​ 3,180 ​ $ 37.56 ​ — ​ ​ 40 Table of Contents (1) Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period. ​ ​ ​ ​ Performance Graph The graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Stock Market (US) Index, the Nasdaq Pharmaceuticals Index, and the S&P 600 Pharmaceuticals, Biotechnology & Life Sciences Index, assuming the investment of $100.00 on December 31, 2017, with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance. ​ ​ ​ 41 Table of Contents Item 6. Reserved ​ ​ 42 Table of Contents